Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Gains from Sales and Divestitures (2017 - 2023)

Ani Pharmaceuticals' Gains from Sales and Divestitures history spans 7 years, with the latest figure at $235000.0 for Q1 2023.

  • For Q1 2023, Gains from Sales and Divestitures rose 45.96% year-over-year to $235000.0; the TTM value through Mar 2023 reached $235000.0, up 45.96%, while the annual FY2022 figure was $245000.0, 96.0% up from the prior year.
  • Gains from Sales and Divestitures for Q1 2023 was $235000.0 at Ani Pharmaceuticals, down from $245000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $245000.0 in Q4 2022 and bottomed at $34000.0 in Q1 2021.
  • The 5-year median for Gains from Sales and Divestitures is $125500.0 (2021), against an average of $126937.5.
  • The largest annual shift saw Gains from Sales and Divestitures crashed 30.61% in 2021 before it skyrocketed 373.53% in 2022.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $42000.0 in 2019, then skyrocketed by 202.38% to $127000.0 in 2020, then decreased by 1.57% to $125000.0 in 2021, then soared by 96.0% to $245000.0 in 2022, then dropped by 4.08% to $235000.0 in 2023.
  • Per Business Quant, the three most recent readings for ANIP's Gains from Sales and Divestitures are $235000.0 (Q1 2023), $245000.0 (Q4 2022), and $234000.0 (Q3 2022).